The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)

TL;DRAbstract

Background HaploBMT with PTCy has now been shown by multiple groups to produce results similar to that seen with matched sibling allogeneic BMT. The use of donor lymphocyte infusion (haploDLI) to treat relapse after haploBMT is not well documented due to theoretical concerns of inducing severe graft-versus-host-disease (GvHD). Here we report our experience of using DLI for relapse after haploBMT. Methods We identified all haploBMT recipients at Johns Hopkins University who received haploDLI for relapse between 6/2003 and 10/2012. Responses were evaluated by standard disease-specific criteria. GvHD was scored using the Keystone and Seattle criteria for acute (a) and chronic (c) GvHD. Duration of survival and response were calculated from date of first haploDLI administration. Patients (pts) were followed till 12/2012. Results Forty pts received 52 haploDLI doses for relapse after haploBMT (16 acute myeloid leukemia [AML], 3 acute lymphoid leukemia [ALL], 5 Hodgkin lymphoma [HL], 7 non-H

Chat with Paper

AI Agents for this Paper